MENU MENU

Event Details

FibroGen Virtual KOL Investor Event Series Part II: FG-3246, a Potential First-in-Class Anti-CD46 Antibody Drug Conjugate (ADC), Development Program in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

06/26/24
10:00 AM EDT

Webcast Presentation

Event Details
Title
FibroGen Virtual KOL Investor Event Series Part II: FG-3246, a Potential First-in-Class Anti-CD46 Antibody Drug Conjugate (ADC), Development Program in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Date / Time
06/26/24
10:00 AM EDT

FibroGen Inc.

Volume:

Minimum 15 minutes delayed. Source: LSEG

Investor and Media Contact